Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3865999 | 0.96 | TLR7 (0.68) | TLR7TLR8 | |
| SCHEMBL25964543 | 0.90 | TLR7 (0.67) | TLR7TLR8 | |
| SCHEMBL5363190 | 0.89 | TLR7 (0.69) | TLR7TLR8 | |
| SCHEMBL3188702 | 0.89 | TLR7 (0.65) | TLR7TLR8 | |
| SCHEMBL25962822 | 0.88 | TLR8 (0.55) | TLR7TLR8 | |
| SCHEMBL5354774 | 0.88 | TLR7 (0.67) | TLR7TLR8 | |
| SCHEMBL5368920 | 0.87 | TLR7 (0.70) | TLR7TLR8 | |
| SCHEMBL842497 | 0.87 | TLR7 (0.69) | TLR7TLR8 | |
| SCHEMBL18610178 | 0.86 | TLR7 (0.62) | TLR7TLR8 | |
| SCHEMBL5368355 | 0.86 | TLR7 (0.62) | TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372511-A1 | ANTIBODY-IMMUNE AGONIST CONJUGATE AND APPLICATIONS THEREOF | GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. (CN) | 2023-11-23 | — | — | US | disclosed |
| US-11717576-B2 | Antibody-immune agonist conjugate and applications thereof | GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. (CN) | 2023-08-08 | — | — | US | disclosed |
| WO-2022188740-A1 | ANTIBODY-IMMUNE AGONIST CONJUGATE AND APPLICATIONS THEREOF | GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. (CN) | 2022-09-15 | — | — | WO | disclosed |
| EP-3344622-B1 | GUANIDINE SUBSTITUTED, FUSED 1H-IMIDAZO[4,5-C]PYRIDINE COMPOUNDS USEFUL IN THE TREATMENT OF VIRAL AND NEOPLASTIC DISEASES | 3M INNOVATIVE PROPERTIES CO (US) | 2021-07-07 | — | — | EP | disclosed |
| CN-108026092-B | Guanidine-substituted imidazo [4,5-c ] ring compounds | 3M创新有限公司 | 2021-01-26 | — | — | CN | disclosed |
| US-10487081-B2 | Guanidine substituted imidazo[4,5-c] ring compounds | 3M INNOVATION PROPERTIES COMPANY (US) | 2019-11-26 | — | — | US | disclosed |
| US-20190055241-A1 | GUANIDINE SUBSTITUTED IMIDAZO[4,5-c] RING COMPOUNDS | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2019-02-21 | — | — | US | disclosed |
| US-10150768-B2 | Guanidine substituted imidazo[4,5-c] ring compounds | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2018-12-11 | — | — | US | disclosed |
| US-20180237435-A1 | GUANIDINE SUBSTITUTED IMIDAZO[4,5-c] RING COMPOUNDS | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2018-08-23 | — | — | US | disclosed |
| EP-3344622-A1 | GUANIDINE SUBSTITUTED IMIDAZO[4,5-c]RING COMPOUNDS | 3M Innovative Properties Company (US) | 2018-07-11 | — | — | EP | disclosed |
| WO-2017040233-A1 | GUANIDINE SUBSTITUTED IMIDAZO[4,5-c] RING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2017-03-09 | — | — | WO | disclosed |
| EP-1638566-A4 | SULFONAMIDE SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES CO (US) | 2009-03-25 | — | — | EP | disclosed |
| EP-1638566-A2 | SULFONAMIDE SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2006-03-29 | — | — | EP | disclosed |
| WO-2005003064-A2 | SULFONAMIDE SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-01-13 | — | — | WO | disclosed |
| WO-2005003065-A2 | SULFONAMIDE SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-01-13 | — | — | WO | disclosed |
| EP-1187613-A4 | AMIDE SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES CO (US) | 2002-07-24 | — | — | EP | disclosed |
| EP-1187613-A1 | AMIDE SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2002-03-20 | — | — | EP | disclosed |
| WO-2000076505-A1 | AMIDE SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
| US-6069149-A | ANTIALLERGENS, ANTIINFLAMMATORY AGENTS | TERUMO KABUSHIKI KAISHA (JP) | 2000-05-30 | — | — | US | disclosed |
| EP-0894797-A1 | NOVEL AMIDE DERIVATIVES AND INTERMEDIATES FOR THE SYNTHESIS THEREOF | TERUMO KABUSHIKI KAISHA (JP) | 1999-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372511-A1 | ANTIBODY-IMMUNE AGONIST CONJUGATE AND APPLICATIONS THEREOF | FCGR1A, FCGR2A, TLR3 | TLR7 28/4885TLR8 27/4885 |
| US-10150768-B2 | Guanidine substituted imidazo[4,5-c] ring compounds | IFNG, IL4, IRF3 | TLR7 55/4885TLR8 163/4885 |
| US-10487081-B2 | Guanidine substituted imidazo[4,5-c] ring compounds | IFNG, IRF3, IL4 | TLR7 63/4885TLR8 211/4885 |
| US-11717576-B2 | Antibody-immune agonist conjugate and applications thereof | FCGR1A, FCGR2A, TLR3 | TLR7 28/4885TLR8 27/4885 |
| US-20190055241-A1 | GUANIDINE SUBSTITUTED IMIDAZO[4,5-c] RING COMPOUNDS | IFNG, IRF3, IL4 | TLR7 63/4885TLR8 211/4885 |
| US-20180237435-A1 | GUANIDINE SUBSTITUTED IMIDAZO[4,5-c] RING COMPOUNDS | IFNG, IL4, IRF3 | TLR7 55/4885TLR8 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.